Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Luminex Corp Lowers FY 2012 Revenue Guidance
Luminex Corp announced that for fiscal 2012, it expects revenue guidance to a range of $200-$204 million from $205-$215 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $207 million for fiscal 2012.
Latest Developments for Luminex Corp
- Luminex Corp Reaffirms FY 2013 Revenue Guidance
- Luminex Corp Receives U.S. FDA Clearance For MAGPIX Instrument With xTAG Gastrointestinal Pathogen Panel
- Luminex Corp Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates
- Luminex Corp Receives FDA Clearance For Comprehensive Gastrointestinal Pathogen Infectious Disease Diagnostic In The United States
Latest Key Developments in Advanced
- Share this
- Link this
- Digg this
Follow Reuters